125 related articles for article (PubMed ID: 3855289)
1. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.
Scher HI; Yagoda A; Ahmed T; Budman D; Sordillo P; Watson RC
Cancer Chemother Pharmacol; 1985; 14(1):79-80. PubMed ID: 3855289
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Kris MG; Gralla RJ; Kelsen DP; Casper ES; Burke MT; Fiore JJ; Cibas IR; Heelan RT
Am J Clin Oncol; 1985 Oct; 8(5):377-9. PubMed ID: 3864366
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
Kavanagh JJ; Yeung KY; Savaraj N; Krakoff IH
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1187-9. PubMed ID: 3865774
[TBL] [Abstract][Full Text] [Related]
4. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
Martoni A; Pacciarini MA; Pannuti F
Eur J Cancer Clin Oncol; 1985 Jul; 21(7):803-6. PubMed ID: 3862582
[TBL] [Abstract][Full Text] [Related]
5. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.
Hakes TB; Daghestani AN; Dougherty JB; Weiselberg L; Raymond V
Cancer Treat Rep; 1985 May; 69(5):559-60. PubMed ID: 3859369
[No Abstract] [Full Text] [Related]
8. Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma.
Stanton G; Casper ES; Friedman B
Cancer Treat Rep; 1985; 69(7-8):915-6. PubMed ID: 3860298
[No Abstract] [Full Text] [Related]
9. Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.
Eridani S; Slater NG; Singh AK; Pearson TC
Blut; 1985 Jun; 50(6):369-72. PubMed ID: 3859341
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses.
Kaplan S; Sessa C; Willems Y; Pacciarini MA; Tamassia V; Cavalli F
Invest New Drugs; 1984; 2(3):281-6. PubMed ID: 6595240
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of 4-demethoxydaunorubicin (DMDR).
Lu K; Savaraj N; Kavanagh J; Feun LG; Burgess M; Bodey GP; Loo TL
Cancer Chemother Pharmacol; 1986; 17(2):143-8. PubMed ID: 3459594
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Stuart NS; Cullen MH; Priestman TJ; Blackledge GR; Tyrrell CJ
Cancer Chemother Pharmacol; 1988; 21(4):351-4. PubMed ID: 3163529
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma.
Harper HD; Kemeny NE; Ahmed T; Cheng E; Arena F; Sordillo P; Faye L
Cancer Treat Rep; 1984 Apr; 68(4):689-90. PubMed ID: 6585273
[No Abstract] [Full Text] [Related]
15. Phase II trial of idarubicin in patients with advanced lymphoma.
Gillies H; Liang R; Rogers H; Harper P; Parapia L; Cox G; Johnson S
Cancer Chemother Pharmacol; 1988; 21(3):261-4. PubMed ID: 3162850
[TBL] [Abstract][Full Text] [Related]
16. 4-Demethoxydaunorubicin administered orally in advanced breast cancer. A phase II study.
De Lena M; Brandi M; Bozzi D; Calabrese P; Romito S
Tumori; 1988 Feb; 74(1):65-70. PubMed ID: 3162625
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma.
Coonley CJ; Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1983 Oct; 67(10):949-50. PubMed ID: 6578873
[No Abstract] [Full Text] [Related]
18. Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
Hochster HS; Green MD; Blum RH; Wernz JC; Speyer JL; Muggia FM
Invest New Drugs; 1986; 4(3):275-8. PubMed ID: 3469171
[TBL] [Abstract][Full Text] [Related]
19. Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study.
Pannuti F; Camaggi CM; Strocchi E; Comparsi R; Angelelli B; Pacciarini MA
Cancer Chemother Pharmacol; 1986; 16(3):295-9. PubMed ID: 3457647
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
Kolarić K; Mechl Z; Potrebica V; Sopkova B
Oncology; 1987; 44(2):82-6. PubMed ID: 3472133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
